Figures
Abstract
Rabies is a neglected zoonotic disease that has no effective treatment after onset of illness. However the disease can be prevented effectively by prompt administration of post exposure prophylaxis which includes administration of passive immunizing antibodies (Rabies Immune Globulin, RIG). Currently, human RIG suffers from many restrictions including limited availability, batch-to batch inconsistencies and potential for contamination with blood-borne pathogens. Anti-rabies monoclonal antibodies (mAbs) have been identified as a promising alternative to RIG. Here, we applied a plant-based transient expression system to achieve rapid, high level production and efficacy of the two highly potent anti-rabies mAbs E559 and 62-71-3. Expression levels of up to 490 mg/kg of recombinant mAbs were obtained in Nicotiana benthamiana glycosylation mutants by using a viral based transient expression system. The plant-made E559 and 62-71-3, carrying human-type fucose-free N-glycans, assembled properly and were structurally sound as determined by mass spectrometry and calorimetric density measurements. Both mAbs efficiently neutralised diverse rabies virus variants in vitro. Importantly, E559 and 62-71-3 exhibited enhanced protection against rabies virus compared to human RIG in a hamster model post-exposure challenge trial. Collectively, our results provide the basis for the development of a multi-mAb based alternative to RIG.
Citation: Tsekoa TL, Lotter-Stark T, Buthelezi S, Chakauya E, Stoychev SH, Sabeta C, et al. (2016) Efficient In Vitro and In Vivo Activity of Glyco-Engineered Plant-Produced Rabies Monoclonal Antibodies E559 and 62-71-3. PLoS ONE 11(7): e0159313. https://doi.org/10.1371/journal.pone.0159313
Editor: Gunnar F. Kaufmann, The Scripps Research Institute and Sorrento Therapeutics, Inc., UNITED STATES
Received: January 16, 2016; Accepted: June 30, 2016; Published: July 18, 2016
Copyright: © 2016 Tsekoa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper.
Funding: LZ and KW are owners of Mapp Biopharmaceutical, a commercial company. MP is employed by Mapp Biopharmaceutical, while JM and SH are employed by Kentucky Bioprocessing, a commercial company. The authors thank the National Research Foundation (SB) (www.nrf.ac.za), Technology Innovation Agency (RC) (www.tia.org.za), the Agricultural Research Council Rabies Diagnostic Cost Centre (15/04/P001) (CS) and Council for Scientific and Industrial Research (SA) (TT, RC) (www.csir.co.za) for funding support. The funders provided support in the form of salaries for authors SB, TT and RC, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.
Competing interests: LZ and KW are owners of Mapp Biopharmaceutical, a commercial company. MP is employed by Mapp Biopharmaceutical, while JM and SH are employed by Kentucky Bioprocessing, a commercial company. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
Introduction
Rabies is a zoonotic viral disease that continues to have no effective treatment after onset of symptoms. Typically, infection occurs after a bite from an infected animal, principally the domestic dog. Other animal species, notably wild carnivores and bats, serve as reservoirs of the rabies virus. Post exposure prophylaxis (PEP) is highly effective when administered promptly. The recommended PEP regimen includes immediate administration of Rabies Immune Globulin (or RIG) from pooled sera taken from hyper-immunized horses (ERIG) or humans (HRIG), as well as vaccination with inactivated Rabies Vaccine and thorough wound cleansing [1, 2].
The majority of the approximately 55,000–70,000 annual human rabies fatalities occur in the developing world, yet access to RIG for adequate PEP is still poor in those countries due to affordability and availability [3, 4]. Both HRIG and ERIG are often in short supply due to the exponential increase in demand for PEP in recent years. In addition, RIG suffers shortcomings such as inconsistency between batches, potential for contamination with blood-borne diseases and, in particular for ERIG, occasional adverse allergic reactions such as serum sickness or anaphylactic shock are observed [5]. For these reasons, an international drive to develop alternative PEP biologics, led by the World Health Organisation (WHO), is underway and replacement of RIG with a safer, efficacious and potentially more economical alternative biologic remains a priority. With the involvement of the WHO Collaborating Centres for Rabies Surveillance and Research, several mouse-derived monoclonal antibodies (mAbs) with rabies virus neutralizing activity have been identified [6]. These mAbs have been targeted for future development to replace RIG as components of a safer new generation for PEP that is affordable for cost-sensitive markets.
Clearly, mAbs have several advantages over RIG including better consistency, improved safety, and with humanization, improved tolerance in patients [7, 8]. Alternatively, due to the specificity of individual neutralizing mAbs for different epitopes on the rabies virus glycoprotein, mAb-based products may have limited potential unless they are formulated as a cocktail to avoid virus escape, improve potency and to broaden their viral neutralization breadth, because there is no single pan-reactive mAb against such diverse lyssaviruses documented to date [9]. Given the specificity of mAb 62-71-3 for antigenic site I, all proposed cocktails from the WHO program so far are envisaged to include 62-71-3, and one of mAbs E559.9.14, M727-5-1, M777-16-3 or 1112–1. Among these, mAb E559 has a broad rabies virus isolate breadth of specificity and potency [6, 9].
The current study describes the plant-based recombinant expression, purification, structural and functional characterisation (in vitro and in vivo) of humanized anti rabies mAbs E559 and 62-71-3. mAbs were expressed in ∆XT/FT, a Nicotiana benthamiana mutant supporting the synthesis of glycan-optimized fucose-free mAbs [10]. Transient expression in plants using virus based vectors was selected as a highly scalable, rapid production alternative to mammalian cell (e.g., CHO cell) culture-based production. Plant expressed mAbs efficiently neutralized a set of virus strains in a cell based Rapid Fluorescent Focus Inhibition test (RFFIT) assay. Moreover, mAbs exhibited enhanced in vivo potency compared to HRIG as determined by a hamster viral challenge model.
Results/Discussion
Recombinant Expression of full length chimeric IgG mAb E559 and 62-71-3 in Nicotiana benthamiana
Variable domains from light and heavy chain (VH and VL) from murine mAbs E559 and 62-71-3 were fused to the constant domain (CH and CL) from human IgG1. These chimeric constructs were plant codon-optimised light chain (LC) and heavy chain (HC) expression constructs with two different signal peptides. These chimeric Ab genes were cloned into two non-competing plant viral vectors, tobacco mosaic virus (TMV) and potato virus X (PVX) backbones [11]. The LC and HC vectors were combined and infiltrated into glycoengineered ΔXTFT Nicotiana benthamiana plants [10] that were monitored for expression of assembled IgG. For both mAbs E559 and 62-71-3 the highest expression levels (456 mg/kg and 455 mg/kg respectively) determined by ELISA were attained during initial expression evaluation using the murine signal peptide in the TMV-HC and the PVX-LC combination (Table 1). The expression levels remained constant upon upscaling the procedure in a highly regulated contract manufacturer environment. These expression levels are higher than that observed when antibodies were expressed using transgenic approaches [12, 13]. These data provide a suitable basis for modelling a scaled-up, economically viable manufacturing process.
Analytical characterisation of plant-produced chimeric mAbs E559 and 62-71-3
Most mAbs can be subject to many potential modifications, including proteolytic clipping, glycosylation, deamidation and oxidation, all of which can affect their efficacy and formulation stability [14]. Therefore, it is important to comprehensively characterise biochemical properties and molecular structures.
Protein A-purified mAbs were characterized by SDS-PAGE under reduced conditions (Fig 1). Both E559 and 62-71-3 heavy chain (HC) bands migrated to their predicted MWs (50 and 25 kDa). Using online LC-ESI-TOF MS was established to elucidate the identity of the mAbs. The deconvoluted multiply charged spectrum of reduced E559 LC is shown in Fig 2(A). The major peak in the spectrum matched the theoretical LC MW of 23,505.87Da. The peaks at 24,398Da, 24,601Da and 24,805Da matched the water-eliminated complex glycans GlcNac2Man3, GlcNac2Man3GlcNac1 and GlcNac2Man3GlcNac2, respectively. In the HC region of E559 only the glycosylated species were observed whilst the native peak at 49,280.18Da was below the limit of detection (Fig 2B).
The middle lane was a PageRuler Prestained Protein Ladder, with the sizes indicated in kDa. The numbered E559 and 62-71-3 bands (1–5) were used for further analysis.
Deconvoluted spectrum of intact, reduced E559 LC (A) and intact, reduced E559 HC (B).Theoretical molecular weights for LC and HC indicated. Detected N-linked glycoforms are shown. The N-glycan nomenclature used was from www.proglycan.com.
The deconvoluted multiply charged mass spectrum of reduced 62-71-3 indicated one major peak in the region of the light chain (LC) at 23,670 Da (Fig 3, inset) and no peaks indicative of glycosylation. A putative glycosylation peak was detected at 50,333 Da, 1,298 Da from the 62-71-3 HC of 49,035Da (Fig 3). The mass difference of 1,298Da was indicative of the complex sugar GlcNac2Man3GlcNac2, with a single water molecule eliminated.
The inset shows the zoomed-in LC region with theoretical molecular weights for LC and HC indicated. Detected N-linked glycoforms are shown. The N-glycan nomenclature used was from www.proglycan.com.
Several mAbs, whose N-glycans lack fucose, have been demonstrated to enhance in vivo efficacy in different models of viral infection [15–17] due to increased ADCC activity. In addition, afucosylated therapeutic anti-cancer antibodies can exhibit superior in vitro and in vivo efficacy [18, 19]. For these reasons, the anti-rabies mAbs were expressed in the ΔXTFT Nicotiana benthamiana host, which is a glycosylation mutant synthesizing predominantly fucose free GnGn glycan structures [10].
To elucidate site-specific glycosylation of the antibodies, respective glycopeptides of HC and LC were analysed by LC-ESI-MS after protein tryptic digest [20]. The glycopeptide profiles of 62-71-3 and E559 HCs were identical and exhibited a single dominant N-glycan species i.e. GlcNac2Man3GlcNac2 (referred to as GnGn) (Fig 4). The major glycan species on the LC of E559 refers to GlcNac2Man3GlcNac1 (GnM). As expected, the LC of 62-71-3 yielded no glycopeptides (data not shown) corroborating findings from the intact LCMS analyses (Fig 3). Our data show that the molecular weight of each mAb precisely matched the mass expected from the deduced amino acid sequence and had the expected glycan profile.
N-glycosylation profile from E559 HC and LC and from 62-71-3 HC as determined by LC-ESI-MS of glycopeptides obtained upon trypsin digestion. Numbers represent the presence of the different glyco-species in percent of total glycan. The N-glycan nomenclature used was from www.proglycan.com.
Secondary and Tertiary structural characterization
To determine structural integrity of plant produced E559 and 62-71-3 secondary and tertiary structure of E559 62-71-3 were determined using Circular Dichroism Spectroscopy (CD: secondary structure probe) and Fluorescence Spectroscopy (FS: tertiary structure probe).
The spectra of native mAb molecules were expected to be dominated by β-sheets with few α-helix conformations found in typical antibodies [21]. The Far-UV CD spectra of the two mAbs were closely related with both mAbs exhibiting minima in the 217 nM region indicating that the secondary structural content is indeed dominated by β-sheets (Fig 5). The tertiary and quaternary structures of E559 and 62-71-3 were compared using FS. Both excitation at 280 nm (combined excitation of Trp and Tyr residues) and 295 nm (selective excitation of Trp residues) were used to monitor global differences between the two mAbs. The E559 has 19 Tyr and 10 Trp residues in the HC and 10 Trp and 2 Tyr in the LC. The 62-71-3 mAb has 18 Tyr and 9 Trp residues in the HC and in the LC it has 10 Trp and 2 Tyr, with residues distributed in a similar manner. At both excitation wavelengths, the λemm max of E559 was shifted to longer wavelengths. This observation indicated a more exposed environment of Trp and Tyr residues for E559 suggesting a more loosely packed quaternary conformation as compared to 62-71-3 (Fig 6).
The mAbs were excited at 280 nm (A) and 295 nm (B). λemm max for each mAb is marked with a dotted line.
Thermal stability
To determine which mAb is more vulnerable to heat induced degradation, the thermal stability was measured by monitoring changes in secondary structural content [22]. The samples were heated continuously at 5°C per minute from 25 oC to 90 oC and far-UV spectra were measured in the region 180–260 nm. Since both mAb structures are dominated by β-sheets, changes at the 217 nm minima, indicative of β-sheet content, was monitored [21]. Differences were observed from 50–55 oC indicating possible rearrangement in secondary structural content in the case of E559. On the other hand, changes in β-sheet content, for 62-71-3, were only observed above 65 oC (Fig 7). Treatment with antibody combinations can be challenging because in spite of their common structure, individual mAbs often have unique and unpredictable responses to their environment related to their stability [23]. This will also be the case with the envisaged E559 / 62-71-3 cocktail where the data suggest E559 is less thermostable than 62-71-3.
Neutralisation potency of plant-made E559 and 62-71-3
The two murine mAbs E559 and 62-71-3 were reported to recognise two complementary sites on the rabies virus glycoprotein [6, 9]. In the current study, it was important to confirm that the chimeric, plant-made versions were effective and secondly, to determine their complimentary efficacy or neutralisation pattern against rabies virus isolates in the context of their potential future application as a cocktail rabies PEP biopharmaceutical.
To test the breadth and coverage of the plant-made E559 and 62-71-3 on 31 laboratory and field isolates of rabies virus, a modified Rapid Fluorescent Focus Inhibition test (RFFIT) was conducted and the neutralisation activity was determined as a 50% end point neutralisation (reciprocal titre). Table 2 and Fig 8 show the neutralisation activities. As expected the mAbs neutralised the laboratory strain CVS-11 but had varied neutralisation activity levels on field isolates of rabies virus from different parts of the world. MAb E559 neutralised all the isolates except Bat 3860, Fox (TX), Dog (Philipine and Argentine), RVHN and Mongoose (South Africa), while both mAbs were not active against Skunk (CA) and Bat Lasiurus cinereus (NY). Because of the difficulty of transferring isolates across national borders, the sample viruses had only two isolates from African countries. The Dog (Tunisia) isolate was neutralised by both mAbs, while mAb 62–713 neutralised the Mongoose (South Africa) isolate while mAb E559 could not. Antibody E559 binds to the discontinuous antigenic sites II while 62-71-3 binds to antigenic site I of the Rabies virus glycoprotein (RVG). As these antibodies have different binding sites, they provide the capacity to simultaneously bind RVG. Use of these two Abs in a cocktail will enhance the neutralization of wider spectra of rabies viruses and reduce the chances of virus escape [9].
In vivo efficacy
The in vivo potency of the plant-produced mAbs was tested in a challenge experiment with female Syrian hamsters infected with CVS-11 (Fig 9). The infected control group did not survive beyond 14 dpi confirming the lethality of the viral inoculum. Animals receiving treatment were administered 2 International Units (IU) of mAb or HRIG. Animals treated with the plant-made mAb E559 (Group 2) showed 100% protection at 14 dpi, slightly higher than that observed with mAb 62-71-3 (Group 3), where 86% of the animals survived at the same time point. At 28 dpi, 33% of animals treated with mAb 62-71-3 and 20% of animals treated with E559 survived; while all animals treated with HRIG died. Collectively, the results show the following order of efficacy: mAb mAb62-71-3>E559>HRIG. The results suggest that the efficacy of plant-made candidates for the cocktail (mAb E559 and mAb 62-71-3) could surpass the commercially available HRIG.
For infected and treated groups, 9 hamsters were in each group, while untreated control groups had 4 hamsters.
Hurdles to further development and the way forward
Although rabies is fatal after the onset of clinical signs, the disease can be readily prevented with existing options for PEP. The compelling need to find a less expensive and safe alternative for RIG alone is not sufficient to pave a smooth path for further development of recombinant mAb-based PEP for implementation in the clinic. The biggest barrier to reaching the market is the complicated and untried clinical development path for the replacement of efficacious immunotherapies for lethal but neglected infectious diseases, such as rabies. In most countries, human efficacy trials for replacement products for these diseases are impossible due to ethical considerations. The US FDA has since 2002 made available an alternative ‘animal rule’ pathway for development where efficacy is established in well-controlled model animal trials and safety in normal human trial pathways. The situation in other parts of world is more complicated and will require coordinated efforts for encouraging regulatory reform on a global level.
There is no set clinical or regulatory path for this type of prophylaxis where it is needed the most, irrespective of whether it was produced from the somewhat novel plant based platform or from the more established mammalian cell culture systems (e.g. CHO cells). Proactive and early engagement with Asian and African regulatory authorities, such as South Africa’s Medicines Control Council, is underway to sensitise them on approval frameworks and market entry elsewhere in the world.
In addition to ethical and regulatory hurdles, global plant-based manufacturing capacity for clinical grade biologics is currently a major barrier. The need for cGMP accredited facilities to enable at-site production for trials and subsequent market penetration has been highlighted before [24]. A shared regional facility model is currently being considered in South Africa, but the main limitation is poor availability of funding from already overstretched public sector budgets.
Materials and Methods
Engineering, cloning and expression of mAbs E559 and 62-71-3
Nicotiana benthamiana codon optimised genes of mAbs 62-71-3 and E559 light and heavy chains were synthesized (Geneart) on the basis of available sequence information. Variable region gene sequences (VH and VL) from murine mAbs E559 and 62-71-3 were grafted onto constant region (CH and CL) sequences from human IgG1. These complete chimeric LC and HC gene sequences were then cloned into two different vectors (ICON Genetics MagnICON vectors pICH26211 and pICH31160 with TMV and PVX viral backbones [11] respectively) with rice alpha amylase and murine signal peptide sequences (designated r and m). This resulted in a total combination of 16 vectors.
Agrobacterium tumefaciens strain ICF320 (ICON genetics, Germany) cultures transformed individually with these vectors were grown and diluted in infiltration medium. To test the expression for each mAb, the 16 gene/vector backbone constructs were infiltrated pair wise in the following combinations: TMV-rHC +PVX-rLC, TMV-mHC + PVX-mLC, PVX-rHC + TMV-rLC, PVX-mHC + TMV-mLC, TMV-rHC + PVX-rLC, TMV-mHC + PVX-mLC, PVX-rHC + TMV-rLC, TMV-mHC + PVX-mLC, TMV-mHC + PVX-mLC, TMV-mHC + PVX-mLC (Table 1). These combinations of vectors were used to transfect 30 days post sow (dps) mutant ΔXTFT glycosylation Nicotiana benthamiana plants. Transfection was done by infiltration in a vacuum chamber at 10 mm Hg. Total protein was extracted from 10 g of leaves 7 days post infiltration (dpi), and assayed for antibody titre using ELISA according to standard techniques.
Production, extraction and purification of antibodies
N. benthamiana plants (ΔXTFT glycosylation mutants) grown for 30 days were vacuum infiltrated with Agrobaterium ICF320 transformed with the optimal combination of LC and HC constructs, as determined above. The recombinant Agrobacterium was diluted in infiltration medium before transfection under vacuum at 10 mm Hg. Nicotiana plants used were previously reported in [10]. Infiltrated plants were allowed to recover and left in the growth room for transient expression and assembly of antibodies. Plants were harvested 7 dpi and homogenised in extraction buffer containing 100 mM Glycine, 40mM Ascorbic Acid, 1mM EDTA (pH 9.5). A 1:1 buffer (l) to harvested plants (kg) ratio was used. The resulting green juice was clarified by filtration through four layers of cheese cloth followed by centrifugation at 10000 x g for 20 minutes. Clarified green juice was loaded onto equilibrated MAb SELECT SURE Protein A affinity resin (GE Healthcare) for capture and first step purification. After a 5 column volume (CV) wash with buffer containing 50 mM Tris, pH 7.4, bound protein was eluted with pH 3 buffer containing 100mM Acetic Acid and immediately neutralized. Eluted samples were then loaded onto an equilibrated Capto Q column (GE Healthcare) and the flowthrough/wash fraction collected. This mAb-containing fraction was finally polished with Ceramic hydroxyapatite (CHT) chromatography with type II resin (Biorad).
Analytical characterisation
Purified mAbs 62-71-3 and E559 were reduced using 20 mM DTT for 15 minute at 50°C. Next, approximately 20 pmol total protein was loaded, using 10% ACN/0.1% FA, on a Jupiter C4 reverse phase column coupled via a switch valve to a QSTAR Elite TOF MS equipped with a TurboIon ESI source. Samples were desalted for 5 minute and eluted using a linear ACN gradient (20–50% in 20 minute at 150 ml/min). Charge state envelopes were collected in the range 700–2000 Da followed by deconvolution of multiply charged data via the Bayesian Protein Reconstruct tool of Analyst QS 2.0. The resulting intact masses of the 62-71-3 and E559 mAb light chain (LC) and heavy chain (HC) were compared to theoretical molecular weights (Mws) obtained using the amino acid sequences of each mAb.
The N-glycosylation profile was determined by LC-ESI-MS as previously described by [20]. In brief, purified IgG was separated by reducing SDS-PAGE, Coomassie stained and the heavy light chain band was excised from the gel. Upon S-alkylation and tryptic or tryptic/GluC digestion, fragments were eluted from the gel with 50% acetonitrile and separated on a Reversed Phase Column (150 × 0.32 mm BioBasic-18, Thermo Scientific) with a gradient of 1–80% acetonitrile. Glycopeptides were analyzed with a Q-TOF Ultima Global mass spectrometer (Waters). Spectra were summed and deconvoluted for identification of glycoforms. Glycans were annotated according to the proglycan nomenclature (www.proglycan.com).
Fluorescence emission spectra were recorded using 3 μM E559 and 62-71-3 in the range 280–450 nm. The excitation and emission slit widths were kept at 5 nm. The spectra were recorded at 23°C, buffer corrected and was an average of three accumulations at a scan speed of 200 nm/min. Readings were taken in a quartz cuvette with a 1 mm path-length using a Shimadzu luminescence spectrometer RF-5301-PC v 2.04 software.
Far-UV-CD spectra (190–250 nm) were recorded using 3 μM E559 and 62-71-3. All CD spectra were recorded at 23°C and represent an average of 3 accumulations, at a scan speed of 100 nm/min. The bandwidth used was 1 nm and the data pitch 0.2 nm. All readings were recorded in a 2 mm cuvette using an Applied Photophysics Chirascan spectropolarimeter and the Spectra Manager software v1.5.00. All spectra were buffer corrected. The spectra were normalised by calculating the mean residue ellipticity [θ] deg.cm2dmol-1residue-1 using the equation [θ] = (100xθ)/cn. Where (θ) is the ellipticity signal in mdeg, c (mM) is the protein concentration, n is the number of residues in the protein chain and l is the path length in cm. All CD spectra were processed using Pro-Data Viewer v4.1.1.
The thermostability of E559 and 62-71-3 were compared by measuring changes in secondary structure using Circular Dichroism. Ellipticity change at 217 nm, reporting on α- β-sheet regions, were recorded with increasing temperatures in the range 25–90°C. Temperature was increased in 5°C increments with a 5 min equilibration time at each temperature. 3 μM of each mAb was used for the experiment. All CD spectra represent an average of 3 accumulations, at a scan speed of 100 nm/min. The bandwidth used was 1 nm and the data pitch 0.2 nm. All readings were recorded in a 2 mm cuvette using a Applied Photophysics Chirascan spectropolarimeter and the Chirascan software v1.5.00.
In vitro efficacy
Neutralisation ability of plant-produced mAb E559 and 62-71-3 was tested against a diverse panel of 31 different rabies virus isolates. To determine the virus neutralising antibody (VNA) titres of the two mAbs, a modification of the Rapid Fluorescent Focus Inhibition test (RFFIT) was used. The titres were calculated using 50% end-point neutralisation (reciprocal titre) of E559 and 62-71-3. Titres <5 indicate absence of neutralization at the concentration tested. Each mAb was at a concentration of 1 mg/ml, as determined spectrophotometrically by absorbance at 280 nm wavelength. To summarise the methodology briefly, all virus isolates were adjusted to ~104 ffu/ ml, mixed with an equal volume of antibody dilution, incubated for 1 hour at 37°C followed by addition of Baby Hamster Kidney (BHK) cells. The virus dose was checked by back titration on every test and results were rejected if virus dose was outside pre-determined limits (i.e. mean±2sd for positive serum and 30-100TCID50/ml for challenge virus).
Animal model challenge
In vivo protective activity of the plant-produced mAbs in vivo was determined by infecting Syrian hamsters with rabies virus strain CVS-11 in the gastrocnemius muscle followed by administration of the test antibodies as part of a PEP regime. The study design included five groups of six-week-old female Syrian hamsters.
Briefly, 2 IU of the relevant mAb or undiluted HRIG [Rabigam, 150 iu/ml, National Bioproducts Institute, Pinetown, South Africa] were introduced intra-peritoneally into hamsters distributed into four groups of 9 hamsters for the experimental groups and four hamsters each for the control groups. In the mAb control groups, hamsters were injected with phosphate buffer (PBS) only (negative control), or commercial HRIG (Rabigam, obtained from National Bioproducts Institute, Durban, South Africa). The PEP was administered 24 hrs after challenge. In the experimental groups, 50 μl of 1 x 106 TCID50/ml of challenge virus standard (CVS-11) was introduced as described in Table 3 below.
Ethics statement
The animal experimental protocols, animal caging and care as well as end point for the animal experiments were approved by the Agricultural Research Council-Onderstepoort Veterinary Institute (ARC-OVI, South Africa) Animal Ethics Committee for the use of living vertebrates for research, diagnostic procedures and product development. The approval application number was AEC36,09 for project number 15/4 P001. Hamsters that survived for 28 days after infection were euthanized with isoflurane.
Acknowledgments
N-glycan analysis was performed by Friedrich Altmann, Department of Chemistry, University of Natural Resources and Life Sciences, Vienna, Austria. We thank Yuri Gleba and Victor Klimyuk, Ion Genetics, GmbH, Halle, Germany for proving MagnICON vectors and L. Greenberg and colleagues at CDC, Atlanta, GA, USA for laboratory technical support. The authors would like to thank the World Health Organization (WHO) for providing monoclonal antibodies and technical advice throughout this project. They would also like to thank the WHO Collaborating Centres who graciously donated these monoclonal antibodies to WHO for the purpose of developing affordable monoclonal antibody cocktails for use in developing countries: WHO Collaborating Centre for Rabies Surveillance and Research, Friedrich-Loeffler-Institute, Wusterhausen, Germany and WHO Collaborating Centre for Reference and Research on Rabies, Centers for Disease Control and Prevention, Atlanta, USA.
Author Contributions
Conceived and designed the experiments: RC LZ KW CS HS CR. Performed the experiments: TT TLS MP HS SS SB WS BP EC SH JM. Analyzed the data: EC TT HS SS CS MP SH JM. Contributed reagents/materials/analysis tools: CS HS CR. Wrote the paper: TT TLS SB EC SS CS WS BP SH JM CR HS MP LZ KW RC.
References
- 1. Shantavasinkul P, Wilde H. Postexposure prophylaxis for rabies in resource-limited/poor countries. Advances in virus research. 2011;79:291–307. pmid:21601051
- 2. Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlertdacha B, Guerra M, et al. Human rabies prevention—United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports / Centers for Disease Control. 2008 May 23;57(RR-3):1–28.
- 3. Knobel D, Cleaveland S, Coleman P. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 2005;83:931–42.
- 4. Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer A, Attlan M, et al. Global Alliance for Rabies Control Partners for Rabies Prevention. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2015 Apr 16;9(4):e0003709. eCollection 2015 Apr. Erratum in: PLoS Negl Trop Dis. 2015 May;9(5):e0003786. pmid:25881058
- 5. Satpathy DM, Sahu T, Behera TR. Equine rabies immunoglobulin: a study on its clinical safety. Journal of the Indian Medical Association. 2005 Apr;103(4):238, 41–2. pmid:16173435
- 6. Muller T, Dietzschold B, Ertl H, Fooks AR, Freuling C, Fehlner-Gardiner C, et al. Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis. 2009;3(11):e542. pmid:19888334
- 7. Both L, Banyard AC, van Dolleweerd C, Horton DL, Ma JK, Fooks AR. Passive immunity in the prevention of rabies. The Lancet Infectious diseases. 2012 May;12(5):397–407. pmid:22541629
- 8. Smith TG, Wu X, Franka R, Rupprecht CE. Design of future rabies biologics and antiviral drugs. Advances in virus research. 2011;79:345–63. pmid:21601054
- 9. Kuzmina N, Kuzmin I, Ellison J, Rupprecht C. Conservation of binding epitopes for monoclonal antibodies on the rabies virus glycoprotein. J Antivir Antiretrovir. 2013;5:039–46.
- 10. Strasser R, Stadlmann J, Schahs M, Stiegler G, Quendler H, Mach L, et al. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant biotechnology journal. 2008 May;6(4):392–402. pmid:18346095
- 11. Giritch A, Marillonnet S, Engler C, van Eldik G, Botterman J, Klimyuk V, et al. Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proceedings of the National Academy of Sciences of the United States of America. 2006 Oct 3;103(40):14701–6. pmid:16973752
- 12. Both L, van Dolleweerd C, Wright E, Banyard AC, Bulmer-Thomas B, Selden D, et al. Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2013 May;27(5):2055–65.
- 13. van Dolleweerd CJ, Teh AY, Banyard AC, Both L, Lotter-Stark HC, Tsekoa T, et al. Engineering, expression in transgenic plants and characterisation of E559, a rabies virus-neutralising monoclonal antibody. The Journal of infectious diseases. 2014 Jul 15;210(2):200–8. pmid:24511101
- 14. Daugherty AL, Mrsny RJ. Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev. 2006 Aug 7;58(5–6):686–706. pmid:16839640
- 15. Forthal DN1, Gach JS, Landucci G, Jez J, Strasser R, Kunert R, Steinkellner H. Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. Immunol. 2010 Dec 1;185(11):6876–82.
- 16. Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, Velasco J, Whaley KJ, Piedra PA, Gilbert BE, Zeitlin L. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5992–7. pmid:24711420
- 17. Pettitt J, Zeitlin L, Kim do H, Working C, Johnson JC, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly MH, Whaley KJ, Ingram MF, Zovanyi A, Heinrich M, Piper A, Zelko J, Olinger GG. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med. 2013 Aug 21;5(199):199ra113. pmid:23966302
- 18. Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, Bossenmaier B, Mueller HJ, Umaña P. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res. 2013 Mar 1;19(5):1126–38. pmid:23209031
- 19. Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, Crocker L, Pabonan O, Baginski T, Meng G, Totpal K, Kelley RF, Sliwkowski MX Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer.Cancer Res. 2010 Jun 1;70(11):4481–9. pmid:20484044
- 20. Stadlmann J, Pabst M, Kolarich D, Kunert R, Altmann F. Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides. Proteomics. 2008 Jul;8(14):2858–71. pmid:18655055
- 21. Doi E, Jirgensons B. Circular dichroism studies on the acid denaturation of gamma-immunoglobulin G and its fragments. Biochemistry. 1970 Mar 3;9(5):1066–73. pmid:5418708
- 22. Liu Y, Huang L, Dong S. Electrochemical catalysis and thermal stability characterization of laccase-carbon nanotubes-ionic liquid nanocomposite modified graphite electrode. Biosens Bioelectron. 2007 Aug 30;23(1):35–41. pmid:17459687
- 23. Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability, and formulation. J Pharm Sci. 2007 Jan;96(1):1–26. pmid:16998873
- 24. Rybicki EP, Chikwamba R, Koch M, Rhodes JI, Groenewald JH. Plant-made therapeutics: an emerging platform in South Africa. Biotechnology advances. 2012 Mar-Apr;30(2):449–59. pmid:21839824